Tools in the assessment of sarcopenia

C. Cooper, R. Fielding, M. Visser, L. J. Van Loon, Y. Rolland, Eric Orwoll, K. Reid, S. Boonen, W. Dere, S. Epstein, B. Mitlak, Y. Tsouderos, A. A. Sayer, R. Rizzoli, J. Y. Reginster, J. A. Kanis

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

This review provides a framework for the development of an operational definition of sarcopenia and of the potential end points that might be adopted in clinical trials among older adults. While the clinical relevance of sarcopenia is widely recognized, there is currently no universally accepted definition of the disorder. The development of interventions to alter the natural history of sarcopenia also requires consensus on the most appropriate end points for determining outcomes of clinical importance which might be utilized in intervention studies. We review current approaches to the definition of sarcopenia and the methods used for the assessment of various aspects of physical function in older people. The potential end points of muscle mass, muscle strength, muscle power, and muscle fatigue, as well as the relationships between them, are explored with reference to the availability and practicality of the available methods for measuring these end points in clinical trials. Based on current evidence, none of the four potential outcomes in question is sufficiently comprehensive to recommend as a uniform single outcome in randomized clinical trials. We propose that sarcopenia may be optimally defined (for the purposes of clinical trial inclusion criteria as well as epidemiological studies) using a combination of measures of muscle mass and physical performance. The choice of outcome measures for clinical trials in sarcopenia is more difficult; co-primary outcomes, tailored to the specific intervention in question, may be the best way forward in this difficult but clinically important area.

Original languageEnglish (US)
Pages (from-to)201-210
Number of pages10
JournalCalcified Tissue International
Volume93
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Sarcopenia
Clinical Trials
Muscles
Muscle Fatigue
Muscle Strength
Epidemiologic Studies
Randomized Controlled Trials
Outcome Assessment (Health Care)

Keywords

  • Muscle fatigue
  • Muscle mass
  • Muscle power
  • Muscle strength
  • Older adults
  • Sarcopenia

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Cooper, C., Fielding, R., Visser, M., Van Loon, L. J., Rolland, Y., Orwoll, E., ... Kanis, J. A. (2013). Tools in the assessment of sarcopenia. Calcified Tissue International, 93(3), 201-210. https://doi.org/10.1007/s00223-013-9757-z

Tools in the assessment of sarcopenia. / Cooper, C.; Fielding, R.; Visser, M.; Van Loon, L. J.; Rolland, Y.; Orwoll, Eric; Reid, K.; Boonen, S.; Dere, W.; Epstein, S.; Mitlak, B.; Tsouderos, Y.; Sayer, A. A.; Rizzoli, R.; Reginster, J. Y.; Kanis, J. A.

In: Calcified Tissue International, Vol. 93, No. 3, 09.2013, p. 201-210.

Research output: Contribution to journalArticle

Cooper, C, Fielding, R, Visser, M, Van Loon, LJ, Rolland, Y, Orwoll, E, Reid, K, Boonen, S, Dere, W, Epstein, S, Mitlak, B, Tsouderos, Y, Sayer, AA, Rizzoli, R, Reginster, JY & Kanis, JA 2013, 'Tools in the assessment of sarcopenia', Calcified Tissue International, vol. 93, no. 3, pp. 201-210. https://doi.org/10.1007/s00223-013-9757-z
Cooper C, Fielding R, Visser M, Van Loon LJ, Rolland Y, Orwoll E et al. Tools in the assessment of sarcopenia. Calcified Tissue International. 2013 Sep;93(3):201-210. https://doi.org/10.1007/s00223-013-9757-z
Cooper, C. ; Fielding, R. ; Visser, M. ; Van Loon, L. J. ; Rolland, Y. ; Orwoll, Eric ; Reid, K. ; Boonen, S. ; Dere, W. ; Epstein, S. ; Mitlak, B. ; Tsouderos, Y. ; Sayer, A. A. ; Rizzoli, R. ; Reginster, J. Y. ; Kanis, J. A. / Tools in the assessment of sarcopenia. In: Calcified Tissue International. 2013 ; Vol. 93, No. 3. pp. 201-210.
@article{8a332d92305348aa9deffbf623342b99,
title = "Tools in the assessment of sarcopenia",
abstract = "This review provides a framework for the development of an operational definition of sarcopenia and of the potential end points that might be adopted in clinical trials among older adults. While the clinical relevance of sarcopenia is widely recognized, there is currently no universally accepted definition of the disorder. The development of interventions to alter the natural history of sarcopenia also requires consensus on the most appropriate end points for determining outcomes of clinical importance which might be utilized in intervention studies. We review current approaches to the definition of sarcopenia and the methods used for the assessment of various aspects of physical function in older people. The potential end points of muscle mass, muscle strength, muscle power, and muscle fatigue, as well as the relationships between them, are explored with reference to the availability and practicality of the available methods for measuring these end points in clinical trials. Based on current evidence, none of the four potential outcomes in question is sufficiently comprehensive to recommend as a uniform single outcome in randomized clinical trials. We propose that sarcopenia may be optimally defined (for the purposes of clinical trial inclusion criteria as well as epidemiological studies) using a combination of measures of muscle mass and physical performance. The choice of outcome measures for clinical trials in sarcopenia is more difficult; co-primary outcomes, tailored to the specific intervention in question, may be the best way forward in this difficult but clinically important area.",
keywords = "Muscle fatigue, Muscle mass, Muscle power, Muscle strength, Older adults, Sarcopenia",
author = "C. Cooper and R. Fielding and M. Visser and {Van Loon}, {L. J.} and Y. Rolland and Eric Orwoll and K. Reid and S. Boonen and W. Dere and S. Epstein and B. Mitlak and Y. Tsouderos and Sayer, {A. A.} and R. Rizzoli and Reginster, {J. Y.} and Kanis, {J. A.}",
year = "2013",
month = "9",
doi = "10.1007/s00223-013-9757-z",
language = "English (US)",
volume = "93",
pages = "201--210",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Tools in the assessment of sarcopenia

AU - Cooper, C.

AU - Fielding, R.

AU - Visser, M.

AU - Van Loon, L. J.

AU - Rolland, Y.

AU - Orwoll, Eric

AU - Reid, K.

AU - Boonen, S.

AU - Dere, W.

AU - Epstein, S.

AU - Mitlak, B.

AU - Tsouderos, Y.

AU - Sayer, A. A.

AU - Rizzoli, R.

AU - Reginster, J. Y.

AU - Kanis, J. A.

PY - 2013/9

Y1 - 2013/9

N2 - This review provides a framework for the development of an operational definition of sarcopenia and of the potential end points that might be adopted in clinical trials among older adults. While the clinical relevance of sarcopenia is widely recognized, there is currently no universally accepted definition of the disorder. The development of interventions to alter the natural history of sarcopenia also requires consensus on the most appropriate end points for determining outcomes of clinical importance which might be utilized in intervention studies. We review current approaches to the definition of sarcopenia and the methods used for the assessment of various aspects of physical function in older people. The potential end points of muscle mass, muscle strength, muscle power, and muscle fatigue, as well as the relationships between them, are explored with reference to the availability and practicality of the available methods for measuring these end points in clinical trials. Based on current evidence, none of the four potential outcomes in question is sufficiently comprehensive to recommend as a uniform single outcome in randomized clinical trials. We propose that sarcopenia may be optimally defined (for the purposes of clinical trial inclusion criteria as well as epidemiological studies) using a combination of measures of muscle mass and physical performance. The choice of outcome measures for clinical trials in sarcopenia is more difficult; co-primary outcomes, tailored to the specific intervention in question, may be the best way forward in this difficult but clinically important area.

AB - This review provides a framework for the development of an operational definition of sarcopenia and of the potential end points that might be adopted in clinical trials among older adults. While the clinical relevance of sarcopenia is widely recognized, there is currently no universally accepted definition of the disorder. The development of interventions to alter the natural history of sarcopenia also requires consensus on the most appropriate end points for determining outcomes of clinical importance which might be utilized in intervention studies. We review current approaches to the definition of sarcopenia and the methods used for the assessment of various aspects of physical function in older people. The potential end points of muscle mass, muscle strength, muscle power, and muscle fatigue, as well as the relationships between them, are explored with reference to the availability and practicality of the available methods for measuring these end points in clinical trials. Based on current evidence, none of the four potential outcomes in question is sufficiently comprehensive to recommend as a uniform single outcome in randomized clinical trials. We propose that sarcopenia may be optimally defined (for the purposes of clinical trial inclusion criteria as well as epidemiological studies) using a combination of measures of muscle mass and physical performance. The choice of outcome measures for clinical trials in sarcopenia is more difficult; co-primary outcomes, tailored to the specific intervention in question, may be the best way forward in this difficult but clinically important area.

KW - Muscle fatigue

KW - Muscle mass

KW - Muscle power

KW - Muscle strength

KW - Older adults

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=84882454913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882454913&partnerID=8YFLogxK

U2 - 10.1007/s00223-013-9757-z

DO - 10.1007/s00223-013-9757-z

M3 - Article

C2 - 23842964

AN - SCOPUS:84882454913

VL - 93

SP - 201

EP - 210

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 3

ER -